Literature DB >> 10894223

[18F]fluorodeoxyglucose positron emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies.

J C Antoine1, L Cinotti, C Tilikete, F Bouhour, J P Camdessanché, C Confavreux, A Vighetto, V Renault-Mannel, D Michel, J Honnorat.   

Abstract

The diagnosis of cancer is often difficult in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Fluorodeoxyglucose 18 positron emission tomography scanning is a highly sensitive and specific method to detect lung tumors. We investigated 15 patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Radiological methods led to the diagnosis of cancer in 12 patients, and test results were negative in 3. Whole-body [18F]fluorodeoxyglucose positron emission tomography showed abnormal uptake in the mediastinum in these 3 patients in accordance with the expected location of the malignancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10894223

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

1.  Strategies in detection of the primary tumour in anti-Yo associated paraneoplastic cerebellar degeneration.

Authors:  Markus Frings; Gerald Antoch; Philipp Knorn; Lutz Freudenberg; Ulrich Bier; Dagmar Timmann; Matthias Maschke
Journal:  J Neurol       Date:  2005-02       Impact factor: 4.849

Review 2.  18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis.

Authors:  Ana María García Vicente; Roberto C Delgado-Bolton; Mariano Amo-Salas; Jesús López-Fidalgo; Ana Paula Caresia Aróztegui; José Ramón García Garzón; Javier Orcajo Rincón; María José García Velloso; María de Arcocha Torres; Soledad Alvárez Ruíz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-27       Impact factor: 9.236

3.  Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.

Authors:  M J Titulaer; R Soffietti; J Dalmau; N E Gilhus; B Giometto; F Graus; W Grisold; J Honnorat; P A E Sillevis Smitt; R Tanasescu; C A Vedeler; R Voltz; J J G M Verschuuren
Journal:  Eur J Neurol       Date:  2010-09-29       Impact factor: 6.089

Review 4.  Diagnosis and current treatment of neurological paraneoplastic syndromes.

Authors:  María José Molina-Garrido; Carmen Guillén-Ponce; Salvador Martínez; María Guirado-Risueño
Journal:  Clin Transl Oncol       Date:  2006-11       Impact factor: 3.405

5.  Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis.

Authors:  T Leyhe; R Schüle; F Schwärzler; T Gasser; T Haarmeier
Journal:  J Neurooncol       Date:  2005-11-29       Impact factor: 4.130

6.  18F-FDG-PET/CT in the diagnosis of paraneoplastic neurological syndromes: a retrospective analysis.

Authors:  Peter Bannas; Christoph Weber; Thorsten Derlin; Jörg Lambert; Frank Leypoldt; Gerhard Adam; Janos Mester; Susanne Klutmann
Journal:  Eur Radiol       Date:  2009-09-30       Impact factor: 5.315

Review 7.  Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates.

Authors:  Sandip Basu; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2008-02-23       Impact factor: 3.488

8.  Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.

Authors:  N Schramm; A Rominger; C Schmidt; J N Morelli; C Schmid-Tannwald; F G Meinel; M F Reiser; C Rist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-03-16       Impact factor: 9.236

9.  Current Therapies for Paraneoplastic Neurologic Syndromes.

Authors:  Myrna R. Rosenfeld; Josep Dalmau
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

Review 10.  Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

Authors:  Meleeneh Kazarian; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2011-03-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.